TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32801102
Drug: Adjunctive eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive eslicarbazepine acetate (ESL) 800 mg once daily (QD)
Study: 33864234
Drug: Continued Behavioral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued Behavioral Weight-Loss Treatment (Control)
Study: 33864234
Drug: Post-Treatment Weight-Related
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-Treatment Weight-Related Experiential Avoidance (AAQW-R)
Study: 34878953
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 440 mg (NapS)
Study: 34878953
Drug: Hydrocodone plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone plus acetaminophen 10/650 mg (HYD+APAP)
Study: 36058564
Drug: Methylprednisolone taper
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone taper (MPT) course following surgery
Study: 32829027
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy (control group)
Study: 35346048
Drug: Intraoperative dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative dopamine infusion
Study: 32436160
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate lozenges
Study: 32436160
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate tablets
Study: 32436160
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets or lozenges)
Study: 35887695
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (AP) 1000 mg
Study: 35887695
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata (AP) 2000 mg
Study: 33526618
Drug: Filgotinib monotherapy
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib monotherapy
Study: 34124817
Drug: Salivary IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary IgA antibodies to MAA‐LDL
Study: 34124817
Drug: Salivary IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary IgA antibodies to heat shock protein 60 of Aggregatibacter actinomycetemcomitans
Study: 34124817
Drug: Salivary IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary IgA antibodies to Porphyromonas gingivalis
Study: 34124817
Drug: Salivary IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary IgA antibodies to A. actinomycetemcomitans
Study: 34124817
Drug: Salivary IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary IgA antibodies to P. intermedia
Study: 34936830
Drug: Cyproheptadine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (8 mg)
Study: 36256912
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily
Study: 36256912
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily alone
Study: 36256912
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in HRR-deficient mCRPC
Study: 36256912
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily alone in HRR-deficient mCRPC
Study: 36256912
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in BRCA2-mutated mCRPC
Study: 36256912
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily alone in BRCA2-mutated mCRPC
Study: 33001491
Drug: TMFI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMFI + ALA-cream
Study: 33001491
Drug: TMFI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMFI + ALA-gel
Study: 33001491
Drug: ALA-cream
Normalized name: hydrocortisone Topical Cream [Ala-Cort]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-cream
Study: 33676327
Drug: Nomogram with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram with independent risk factors (older age ≥65 years, female gender, hemorrhagic stroke, malignancy, lower limb muscle strength <3 grade, Albumin <40 g·L−1, D‐dimer >0.5 mg·L−1)
Study: 33843663
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (OT) group, 20-25 μg/ml ozone concentration, 30 ml, 8 sessions total
Study: 33843663
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (PC) group, 0.1 μg/ml ozone concentration, 30 ml, 8 sessions total
Study: 32127336
Drug: Low-dose prasugrel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prasugrel (5 mg)
Study: 35776501
Drug: GAD-alum (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (4 μg) administered intralymphatically three times with 1 month interval
Study: 35869467
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (Control group)
Study: 32856619
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of a carbohydrate beverage
Study: 32446951
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone before radiation therapy followed by 3 daily doses (group A)
Study: 32446951
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone followed by 3 doses of placebo (group B)
Study: 32446951
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of placebo (group C)
Study: 33547676
Drug: CGRP monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP monoclonal antibody
Study: 35033011
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of PPI (Group A)
Study: 35033011
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of PPI (Group B)
Study: 33856549
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus topical ketorolac
Study: 33501601
Drug: HCB (HCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCB (HCD supplemented with 50 mg/kg berberine)
Study: 34435584
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg, 300 mg, 600 mg (single doses)
Study: 32694286
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation oral contraceptives (OC)
Study: 32694286
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of oral contraceptives (non-OC)
Study: 36424580
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg subcutaneously daily for a mean of 18 months (range 14–24 months)
Study: 32024027
Drug: Sucrosomial ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrosomial ferric pyrophosphate plus L‐ascorbic acid (30-day oral therapy)
Study: 32327497
Drug: PEGasparaginase individualized
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEGasparaginase individualized dosing based on therapeutic drug monitoring
Study: 32327497
Drug: PEGasparaginase during
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEGasparaginase during induction treatment
Study: 32327497
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of PEGasparaginase
Study: 32070417
Drug: Web-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based treatment program with therapist guidance
Study: 39082471
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARB)
Study: 35789991
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 IU monthly for 5 years)
Study: 33785488
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (unsupervised exercises and referral for physiotherapy or exercise therapy upon request)
Study: 35710440
Drug: Clindamycin capsules
Normalized name: clindamycin Oral Capsule
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin capsules for 10 days
Study: 35241469
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with an aromatase inhibitor (AI)
Study: 35241469
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with fulvestrant
Study: 32589632
Drug: Household Treatment
Normalized name: ALLERGENIC EXTRACT INSECTS HOUSEHOLD INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household Treatment group (all family members treated)
Study: 32589632
Drug: Individual Treatment
Normalized name: Alex Rubber Tip Individual Pack 3/4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Treatment group (only affected participants treated)
Study: 32589632
Drug: Household Treatment
Normalized name: ALLERGENIC EXTRACT INSECTS HOUSEHOLD INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household Treatment group
Study: 32589632
Drug: Individual Treatment
Normalized name: Alex Rubber Tip Individual Pack 3/4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Treatment group
Study: 36038262
Drug: Treg infusions
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg infusions (1 × 10^6 cells/kg) IV every 4 weeks and IL-2 (2 × 10^5 IU/m2) injections 3 times/week
Study: 36038262
Drug: Treg infusions
Normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg infusions (2 × 10^6 cells/kg and 3 × 10^6 cells/kg) in OLE
Study: 36038262
Drug: Treg/IL-2 treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg/IL-2 treatments
Study: 33818395
Drug: Treatment app
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment app (including pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, tailored advice, exercise log, reinforcement messages, and reminders)
Study: 33818395
Drug: Treatment app
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment app
Study: 36476386
Drug: Online behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online behavior change intervention with weekly individual online sessions for 12 weeks and an activity monitor
Study: 36476386
Drug: Weekly individual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly individual online sessions for 12 weeks
Study: 34117190
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention addressing living with a PCN tube, provided twice (before placement and at first tube change, 6 weeks later)
Study: 39663175
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT)
Study: 35022779
Drug: COVID-19-directed therapies
Normalized name: DIRECT BLACK 19
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19-directed therapies
Study: 38507688
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids
Study: 35724261
Drug: Amoxicillin-Potassium Clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-Potassium Clavulanate
Study: 34470831
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (100 mg biweekly, total 2 grams)
Study: 34470831
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (500 mg every 10 weeks, total 2 grams)
Study: 34470831
Drug: Erythropoiesis stimulating
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis stimulating agent dosing
Study: 35555966
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of triamcinolone acetonide
Study: 35555966
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser therapy followed by topical application of the drug for six sessions
Study: 33059771
Drug: Adsorbed COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac, 3 μg/0.5 mL (600 SU per dose), two doses IM with a two-week interval.
Study: 33059771
Drug: Placebo containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo containing aluminium hydroxide in a 0.5 mL solution, two doses IM with a two-week interval.
Study: 32909643
Drug: apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 30 mg b.i.d.
Study: 35304977
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 200 mg cyclosporine
Study: 35304977
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 600 mg quinidine
Study: 33687763
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (etoposide and carboplatin or cisplatin)
Study: 36471257
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy (no therapy)
Study: 33773120
Drug: Riociguat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (up to 2.5 mg three times per day)
Study: 33773120
Drug: PDE5i (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE5i (oral sildenafil [≥60 mg per day] or oral tadalafil [20–40 mg per day])
Study: 32546647
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint blockade (ICB) therapy
Study: 32546647
Drug: IDO enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO enzyme inhibitor treatment
Study: 33580944
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (30 mg/kg, six doses each 5 mg/kg, biweekly for 3 weeks)
Study: 33580944
Drug: Miltefosine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (2.5 mg/kg or 100 mg/day for 12 weeks)
Study: 35925752
Drug: 1.8 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/day liraglutide
Study: 32828393
Drug: Biotin supplementation
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biotin supplementation at 0.3 mg/L (T1) and 0.45 mg/L (T2) in drinking water for older hens (53-56 weeks)
Study: 33167773
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 g/day)
Study: 32092343
Drug: High-dose-rate brachytherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate brachytherapy boost (HDRB)
Study: 32092343
Drug: 66 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66 Gy external beam radiation therapy (EBRT)
Study: 32092343
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy external beam radiation therapy (EBRT)
Study: 32092343
Drug: 74 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 74 Gy external beam radiation therapy (EBRT)
Study: 36184124
Drug: Carotegrast methyl
Normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotegrast methyl 480 mg
Study: 36184124
Drug: Carotegrast methyl
Normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotegrast methyl 960 mg
Study: 32797382
Drug: Universal HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal HIV testing and treatment (UTT) including home-based and mobile testing, active linkage to care, rapid ART start, and enhanced male circumcision services.
Study: 35775502
Drug: Universal HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal HIV testing and treatment (UTT)
Study: 35997234
Drug: L-menthol ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol ingestion (M-IG)
Study: 35997234
Drug: L-menthol mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol mouth rinsing (M-MR)
Study: 32192644
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 or 150 mg every 2 weeks)
Study: 35236763
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume recruitment (LVR) twice daily for 2 years
Study: 35140347
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of the µ‐opioid agonist morphine sulfate
Study: 35974938
Drug: Levetiracetam (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1000 mg)
Study: 35974938
Drug: Lamotrigine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (250 mg)
Study: 33689731
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg TDS, up-titrated to 30 mg/day after one week)
Study: 33689731
Drug: Fludrocortisone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.05 mg BD, up-titrated to 0.2 mg/day after one week)
Study: 32930386
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (n = 2029)
Study: 32179023
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention to improve vaccination rates including designation of an immunization champion, purchasing vaccines, guidance on storage and management, routine identification of eligible patients, standing orders for vaccination, and vaccine administration.
Study: 33594386
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine hydrochloride film (APL‐130277, Kynmobi) administered up to 5 times a day
Study: 35850436
Drug: Lithothamnion (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithothamnion (100 mg/kg bw PO BID) for 7 days before oligofructose intake (10 g/kg PO)
Study: 35872954
Drug: Overall oral
Normalized name: Feverall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall oral care (observation group)
Study: 35872954
Drug: Basic oral
Normalized name: sodium phosphate, dibasic Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic oral care (control group)
Study: 38183804
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for insomnia (CBT-I)
Study: 34692725
Drug: Silybin-phospholipids complex
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (wild type treated group)
Study: 34692725
Drug: Silybin-phospholipids complex
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (mutated treated group)
Study: 34181714
Drug: cPass neutralization
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: cPass neutralization antibody assay
Study: 32118260
Drug: Self-reported daily
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported daily abstinence
Study: 33836800
Drug: ChemoRadiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChemoRadiation and Immunotherapy (CRIO) with durvalumab (anti-PD-L1 checkpoint inhibitor)
Study: 35469779
Drug: Auditory, tactile,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory, tactile, visual, and vestibular with odor from a baby lotion (ATVVO)
Study: 38345741
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (LCIG)
Study: 33093598
Drug: Levodopa-entacapone-carbidopa intestinal
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-entacapone-carbidopa intestinal gel (LECIG)
Study: 33989106
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (20 µg) of recombinant hepatitis B vaccine
Study: 33989106
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (60 µg) of recombinant hepatitis B vaccine
Study: 32951731
Drug: Intravenous Gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Gamma Globulin (IVIG)